dA-NHbenzylOCF3

dA-NHbenzylOCF₃ (0.001-100 µM; 48-72 h) exhibits low cytotoxicity against PC3, MCF-7 and HaCaT cells, with statistically significant decreases in cell viability observed only at 20 µM (PC3, 72 h) and 100 µM (all cell lines, 48/72 h)^[1].
dA-NHbenzylOCF₃ (20 µM; administered 48 h prior to irradiation with 1, 3, 4 Gy) significantly enhances the radiosensitivity of PC3 and MCF-7 cells to X-rays at a statistical level, with stronger activity against PC3 cells (an α elevation factor of 2.1 versus 1.5 for MCF-7 cells), and the dose enhancement factors are 1.30 (PC3) and 1.21 (MCF-7), respectively^[1].
When combined with X-ray irradiation, dA-NHbenzylOCF₃ (20 µM; treated for 48 h before 8 Gy irradiation; incubated for 24 h after irradiation) regulates the cell cycle progression of PC3 and MCF-7 cells, increases the proportion of cells in the radiation-sensitive G2/M phase, and this effect is more pronounced in PC3 cells^[1].
dA-NHbenzylOCF₃ (20-100 µM; 48 h) penetrates PC3 cells, localizes primarily in the cytoplasm (with a cytoplasm-to-nucleus ratio ranging from 26:1 to 22:1), and exists exclusively in the non-phosphorylated form^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.